Viridian Capital Leads Financing for Israel's Leading Cannabis Biotech Company
Breath of Life Pharma Raises $11.1M in Growth Capital
(New York, NY, September 4, 2018) Breath of Life Pharma (“BOL Pharma” or the “Company”), an Israel-based cannabis biotech company conducting numerous clinical trials in Israel, has closed an $11.1-million growth capital round that was oversubscribed. Viridian Capital Advisors ("VCA"), through its broker dealer Pickwick Capital Partners, LLC (Member of FINRA/SIPC) served as the placement agent for the Company.
Breath of Life Pharma (www.bolpharma.com) is leveraging its experience as one of Israel’s original seven licensed medical cannabis growers to conduct FDA-compliant clinical trials on human populations. Led by premier scientists in Israel and conducted in Israel’s leading hospitals, BOL Pharma is conducting Phase 2 clinical trials on patients with disease states ranging from childhood autism to osteoarthritis, diabetic neuropathic pain, chronic back pain, and fibromyalgia. With the proceeds from this capital raise, BOL Pharma will be conducting the largest portfolio of medical cannabis Phase 2 clinical trials globally.
Dr. Tamir Gedo, BOL Pharma’s CEO, commented, “Viridian Capital Advisors has been an essential strategic partner in not only leading the structuring, valuation, and closing of our first outside capital raise, but also in providing a range of strategic value to our company. Viridian introduced the first two independent members of our Board of Directors, enhanced our intercompany and shareholder agreements, helped to close funding from a U.S. university, and sourced other strategic partnerships in Canada and the U.S. We valued their guidance throughout this process and will continue to do so going forward."
Scott Greiper, President of Viridian Capital Advisors, commented, “Dr. Tamir Gedo is building BOL Pharma into a premier, next generation medical cannabis biotechnology and pharmaceutical company involved in the entire value chain from strain to formulation to drug delivery method. BOL Pharma is filling a critical information gap in the global cannabis industry by conducting clinical trials to prove the efficacy of medical cannabis in a range of human disease states - The market is currently lacking efficacy data from proper clinical trials which are greatly restricted in the U.S. due to cannabis' federal illegality."
BOL Pharma’s sister company, BOL Industries, is accredited in Good Manufacturing Practices (GMP) and Good Agricultural Practices (GAP) throughout the entire value chain and provides BOL Pharma with commercial-scale quantities of FDA-compliant, pharmaceutical-grade active pharmaceutical ingredients (APIs). This enables BOL Pharma to conduct multiple FDA-compliant clinical trials and to gain a first-mover advantage in medical cannabis product sales in Israeli pharmacies, ultimately positioning BOL as a gateway for future export sales.”
About Viridian Capital Advisors, LLC
Viridian Capital Advisors (www.viridianca.com) is a financial and strategic advisory firm dedicated to the cannabis market. We are a data- and market intelligence-driven firm that provides investment banking, M&A, corporate development, and investor relations services to emerging growth companies and qualified investors in the cannabis sector. Our banking practice, through broker-dealer Pickwick Capital Partners, LLC (Member FINRA/SIPC), provides capital and M&A to fund the growth of our clients, while our advisory practice helps to position and build their businesses. Our team’s decades of high level operating and transactional experience on Wall Street in a variety of emerging sectors, allows Viridian to provide comprehensive strategic and financial solutions that assist cannabis enterprises in realizing their full potential.
Marijuana remains illegal under federal law. The Federal Government does not recognize marijuana to have any medicinal values. Marijuana cultivation, possession, consumption, sales, and distribution are illegal under federal laws and also certain state laws. Please note that there are differences in marijuana laws from one state, county, or city to another.
Contact
Harrison Phillips
Vice President
Viridian Capital Advisors, LLC
(212) 209-3086
[email protected]
Breath of Life Pharma (www.bolpharma.com) is leveraging its experience as one of Israel’s original seven licensed medical cannabis growers to conduct FDA-compliant clinical trials on human populations. Led by premier scientists in Israel and conducted in Israel’s leading hospitals, BOL Pharma is conducting Phase 2 clinical trials on patients with disease states ranging from childhood autism to osteoarthritis, diabetic neuropathic pain, chronic back pain, and fibromyalgia. With the proceeds from this capital raise, BOL Pharma will be conducting the largest portfolio of medical cannabis Phase 2 clinical trials globally.
Dr. Tamir Gedo, BOL Pharma’s CEO, commented, “Viridian Capital Advisors has been an essential strategic partner in not only leading the structuring, valuation, and closing of our first outside capital raise, but also in providing a range of strategic value to our company. Viridian introduced the first two independent members of our Board of Directors, enhanced our intercompany and shareholder agreements, helped to close funding from a U.S. university, and sourced other strategic partnerships in Canada and the U.S. We valued their guidance throughout this process and will continue to do so going forward."
Scott Greiper, President of Viridian Capital Advisors, commented, “Dr. Tamir Gedo is building BOL Pharma into a premier, next generation medical cannabis biotechnology and pharmaceutical company involved in the entire value chain from strain to formulation to drug delivery method. BOL Pharma is filling a critical information gap in the global cannabis industry by conducting clinical trials to prove the efficacy of medical cannabis in a range of human disease states - The market is currently lacking efficacy data from proper clinical trials which are greatly restricted in the U.S. due to cannabis' federal illegality."
BOL Pharma’s sister company, BOL Industries, is accredited in Good Manufacturing Practices (GMP) and Good Agricultural Practices (GAP) throughout the entire value chain and provides BOL Pharma with commercial-scale quantities of FDA-compliant, pharmaceutical-grade active pharmaceutical ingredients (APIs). This enables BOL Pharma to conduct multiple FDA-compliant clinical trials and to gain a first-mover advantage in medical cannabis product sales in Israeli pharmacies, ultimately positioning BOL as a gateway for future export sales.”
About Viridian Capital Advisors, LLC
Viridian Capital Advisors (www.viridianca.com) is a financial and strategic advisory firm dedicated to the cannabis market. We are a data- and market intelligence-driven firm that provides investment banking, M&A, corporate development, and investor relations services to emerging growth companies and qualified investors in the cannabis sector. Our banking practice, through broker-dealer Pickwick Capital Partners, LLC (Member FINRA/SIPC), provides capital and M&A to fund the growth of our clients, while our advisory practice helps to position and build their businesses. Our team’s decades of high level operating and transactional experience on Wall Street in a variety of emerging sectors, allows Viridian to provide comprehensive strategic and financial solutions that assist cannabis enterprises in realizing their full potential.
Marijuana remains illegal under federal law. The Federal Government does not recognize marijuana to have any medicinal values. Marijuana cultivation, possession, consumption, sales, and distribution are illegal under federal laws and also certain state laws. Please note that there are differences in marijuana laws from one state, county, or city to another.
Contact
Harrison Phillips
Vice President
Viridian Capital Advisors, LLC
(212) 209-3086
[email protected]
Copyright © 2018 Viridian Capital Advisors, LLC, All rights reserved.
Our mailing addresses are:
Viridian Capital Advisors, LLC
885 Third Avenue
20th Floor
New York, NY 10022
Pickwick Capital Partners, LLC
445 Hamilton Avenue
Suite 1102
White Plains, NY 10601
Broker-Dealer Services Provided Through Pickwick Capital Partners, LLC - A Member of FINRA and SIPC
Our mailing addresses are:
Viridian Capital Advisors, LLC
885 Third Avenue
20th Floor
New York, NY 10022
Pickwick Capital Partners, LLC
445 Hamilton Avenue
Suite 1102
White Plains, NY 10601
Broker-Dealer Services Provided Through Pickwick Capital Partners, LLC - A Member of FINRA and SIPC
